FORM PTO-1449 (Modified)

٠,

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessary) JUN 1 5 2001 &

DATERIT DOCLIRACAITS

APPLICANT

FILING DATE

ATTY. DOCKET NO.

Kurt M. Kesseler

January 16, 2001

HMR 2041 US NP1

| \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ | | -46 | > / | | | | | · · | U.S. | PATENT DO | COMEN 12 | | | |
|--|-------|--------|---------------|----|-----|-----|-----|-----|-------------|-----------|----------------|-------|---------|---------------------------|
| EXAMINER INITIALS | & TRI | DEMARY | | DO | CUM | ENT | NUM | BER | , | DATE | NAME | CLASS | SUBCLAS | FILING DATE IF APPRORIATE |
| a | | | 4 | 9 | 0 | 0 | 7 | 2 | 7 | 2/13/1990 | Kattige et al. | 514 | 2/2 | 1/26/1989 |
| v | | | 5 | 2 | 8 | 4 | 8 | 5 | 6 | 2/8/1994 | Naik et al. | 514 | 320 | 1/26/1989 |
| | | | | | | | | | | | | / | | |
| | | | 1. | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS | * | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLAS S | TRANSI YES NO | ATION |
|-------------------|---|-----------------|---|---|---|---|---|---|--------|---------|-------|--------------|---------------------|-------|
| w | | 0 | 3 | 6 | 6 | 0 | 6 | 1 | 2/5/90 | EPO | | | | No |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | • |
| | | | | | | | | | | | | | | |

| | | OTHER DOCUMENTS |
|-------------------|---|---|
| EXAMINER INITIALS | * | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC. |
| w | | Li, Ping-et-al: "Evaluation of Intravenous Flavopiridol-Formulations" PDA J. Phar. Sci. Technol. (1999), 53(3), 137-140 |
| V | | Sedlacek et al.: "Flavopiridol, a New Kinase Inhibitor for Tumor Therapy", Int. J. Oncology, Vol. 9, pgs. 1143-1168 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| EXAMINER | els | DATE CONSIDERED | 12/18/01 |
|----------|---------|-----------------|----------|
| | Q_{-} | | , , () |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.